# IDEXX Shares Surge as Veterinary Diagnostics Lift Its 2026 Outlook

Shares in the animal-health diagnostics company jumped Monday after third-quarter revenue rose 10% and management raised its full-year revenue and earnings forecasts.

By Will Langan | 24X7 News
Published: 2026-11-02T21:31:13.291Z
Updated: 2026-11-02T21:31:13.291Z
Section: Business
Format: News
Canonical: https://24x7news.us/articles/idexx-shares-surge-veterinary-diagnostics-outlook-november-2-2026

IDEXX Laboratories shares surged Monday, November 2, after the veterinary diagnostics company reported stronger-than-expected third-quarter earnings and raised its full-year forecast. The rally was one of the most prominent company-specific moves in U.S. stocks during a session when the broader market's technology-heavy indexes fell.

The Westbrook, Maine-based business reported quarterly revenue of $1.214 billion, an increase of 10% from a year earlier on both a reported and organic basis. Diluted earnings per share rose to $4.01 from the year-earlier figure, representing 18% reported growth, according to the company's filing and investor release.

IDEXX raised its 2026 sales guidance to $4.741 billion to $4.767 billion, and lifted its earnings-per-share forecast to $14.96 to $15.16. The revised guidance incorporates better-than-expected diagnostics revenue and the effects of a recent software acquisition.

Companion-animal diagnostics recurring revenue increased 11%. Growth came from laboratory services, test consumables and use of diagnostic equipment at veterinary practices. The company said it placed more than 1,900 new inVue Dx analyzers in the quarter, bringing the installed base to nearly 11,000 instruments.

Investors rewarded the results even as the broader veterinary sector faces fewer office visits in some regions. Barron's reported that U.S. veterinary visits declined in the quarter, while IDEXX's recurring testing and related-product revenues kept expanding. That divergence suggests a clinic can buy more testing products even when the total number of visits remains under pressure.

The company's gross margin rose to 62.9% from 61.8% a year earlier, while its operating margin increased to 33.1%. IDEXX said growth and productivity improvements more than offset some of the costs associated with its expansion.

Market coverage reported double-digit stock gains Monday, with the percentage changing throughout the session. Investors are watching whether new diagnostic products and veterinary software can maintain that growth if consumers continue to limit some discretionary spending on pet care.

The latest report shows the company performing well in the recent quarter, but management's guidance remains a forecast rather than a guarantee of future sales or profit.

Sources:
- IDEXX Laboratories, third-quarter 2026 results and SEC exhibit, November 2
- Barron's, IDEXX stock reaction and veterinary trends, November 2
- IDEXX Laboratories, company earnings announcement, November 2

## Sources
- IDEXX Laboratories, third-quarter 2026 results and SEC exhibit, November 2: https://ir.idexx.com/sec-filings/all-sec-filings/content/0001104659-26-120892/tm2628647d1_ex99-1.htm
- Barron's, IDEXX stock reaction and veterinary trends, November 2: https://www.barrons.com/articles/idexx-earnings-stock-price-d3deebd4
- IDEXX Laboratories, company earnings announcement, November 2: https://ir.idexx.com/news-events/press-releases/detail/420/idexx-laboratories-announces-third-quarter-results